Please note that masks must still be worn within NYOH practices regardless of vaccination status.
Learn more about this and other COVID-19 related updates

Clinical Trials & Research

PH2 Tuca+ Tras HER2+ CC

MOUNTAINEER: A Phase 2, Open Label Study of Tucatinib Combined with Trastuzumab in Patients with HER2+ Metastatic Colorectal Cancer (ACCRU-GI-1617, SGNTUC-017)

Disease Types: Colorectal,&nbs

Available at: {clinical_trial_location backspace="7"}PH2 Tuca+ Tras HER2+ CC, {/clinical_trial_location}

Principal Investigator: {clinical_trial_principle_investi} , {/clinical_trial_principle_investi}